A gain of function paradox: Targeted therapy for glioblastoma associated with abnormal NHE9 expression.

ABSTRACT: Glioblastoma (GBM) is the most frequent and inevitably lethal primary brain cancer in adults. It is recognized that the overexpression of the endosomal Na⁺ /H⁺ exchanger NHE9 is a potent driver of GBM progression. Patients with NHE9 overexpression have a threefold lower median survival relative to GBM patients with normal NHE9 expression, using available treatment options. New treatment strategies tailored for this GBM subset are much needed. According to the prevailing model, NHE9 overexpression leads to an increase in plasma membrane density of epidermal growth factor receptors (EGFRs) which consequently enhances GBM cell proliferation and migration. However, this increase is not specific to EGFRs. In fact, the hallmark of NHE9 overexpression is a pan-specific incre

SUBMITTER: Pall AE 

PROVIDER: S-EPMC6815843 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature